Group 1 - The company, Jinfang Pharmaceutical-B (02595), has been included in multiple indices, including the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Index, and Hang Seng Innovative Drug Index, effective March 9, 2026 [1] - The company will also be added to the MSCI Global Small Cap Index, with the adjustment effective after the market close on February 27, 2026 [1] - Inclusion in these indices will allow the company's stock to be traded through the Hong Kong Stock Connect and Shenzhen Stock Connect, enhancing its accessibility to investors [1] Group 2 - The company is also selected for several other Hang Seng indices, such as the Hang Seng Composite Small Cap Index and the Hang Seng Healthcare Index, reflecting investor recognition of its value and growth potential [2] - The board anticipates that this inclusion will improve stock liquidity, broaden the shareholder base, and diversify the types of shareholders, contributing to the company's long-term stable development [2] - The company aims to strengthen its leading position in the RAS sector and enhance its international competitiveness in innovative drug fields, driving value creation through its R&D advantages [2]

Group 1 - The stock price of TIDE Pharmaceutical (03880.HK) increased by 8.77% to close at HKD 26.30, driven by the overall strength of the Hong Kong pharmaceutical sector and positive company fundamentals [1] - TIDE Pharmaceutical's stock opened at HKD 24.20, reached a high of HKD 26.60, with a trading range of 9.93%. The Hong Kong pharmaceutical sector was active, with peers like Baijie Pharmaceutical-B rising over 8% and Zai Lab increasing over 6% [2] - The company focuses on peptide CDMO business, serving clients in over 50 countries with a client retention rate exceeding 90%. The financial report for the first half of 2025 showed a revenue increase of 28.52% year-on-year and a 101.71% increase in profit attributable to shareholders, supported by growing demand for GLP-1 related drug development [3] Group 2 - The innovation drug sector's valuation has adjusted to a relatively low level, with the Hong Kong innovation drug index valuation falling to the 24th percentile over the past five years, attracting capital back into the market. Policy emphasis on "domestic demand as the main driver" has boosted expectations for the pharmaceutical industry [3] - The current price-to-earnings ratio (TTM) for TIDE Pharmaceutical is 30.75 times, which is higher than the average level of the Hong Kong pharmaceutical sector, necessitating attention to the sustainability of earnings and valuation alignment [4] - The competitive landscape in the GLP-1 sector is intensifying, with a dense pipeline of research and development. The expiration of the semaglutide patent in 2026 may lead to a concentration of generic drug launches, potentially squeezing profit margins [4]

Macro Perspective - Since 2025, China's economy has increasingly shown characteristics of "new and superior" development, with new productive forces being cultivated and diverse consumer preferences becoming more prominent[3] - High-tech manufacturing PMI was 52.0% in January 2026, consistently outperforming the overall manufacturing PMI of 49.3%[21] - High-tech industries' added value grew by 11.0% year-on-year in December 2025, exceeding the overall industrial enterprises' growth by 5.8 percentage points[21] Industry Perspective - Investment in advanced manufacturing, such as aerospace and automotive, grew by 16.9% and 11.7% respectively, outpacing overall manufacturing investment growth[25] - The information technology service sector saw an investment increase of 28.4%, maintaining over 25% growth for 11 consecutive months[25] - The revenue growth of strategic emerging services was 9.9%, while high-tech services grew by 8.6%, both surpassing the overall service sector growth of 7.8%[24] Market Perspective - As of January 2026, the market capitalization weight of the A-share information and communication sector reached 24%, surpassing financial and real estate sectors at 19%[3] - The market capitalization of A-share new economy MAG7 stocks is below that of US MAG7 stocks (20%+) and Hong Kong stocks (10+%), indicating room for growth[3] - The performance of A-share strategic emerging industries showed a profit growth of 15.5%, exceeding the overall non-financial A-share sector's growth of 13.8%[38] Outlook and Risks - The transition from old to new economic drivers is expected to accelerate, positioning new economic sectors as the main growth engine for China's economy[3] - Key investment areas include technology innovation and advanced manufacturing, particularly in AI and innovative pharmaceuticals[3] - Risks include potential market learning effects, unexpected tightening of macro and industrial policies, and significant changes in macroeconomic conditions and liquidity[3]

Core Viewpoint - The article emphasizes the importance of "long-term" and "contrarian" investment strategies, focusing on the essence of business and long-term trends rather than short-term market emotions and price trends [1][2]. Group 1: Investment Strategy - The company prioritizes finding investment opportunities with asymmetric risk-reward characteristics, specifically those that are significantly undervalued, rather than merely low-priced or low PB/PE stocks [2][3]. - Successful contrarian investment opportunities should not only be undervalued but also have a strong potential for future recognition and appreciation [2][3]. Group 2: Market Dynamics - Significant price discrepancies often arise from the market's tendency to linear extrapolate past performance, while the actual business environment may experience nonlinear changes [3][5]. - Historical examples illustrate how market expectations can lag behind actual industry performance, leading to substantial investment opportunities when the market eventually corrects its views [4][5]. Group 3: Value Drivers - Two key conditions for identifying attractive investment opportunities are: 1) a significant expectation gap where the market currently does not recognize the potential, and 2) strong value tension that will compel future recognition [3][7]. - The article highlights that strong value tension arises from powerful industry trends, excellent business fundamentals, and efficient operations, which together create a compelling investment case [9][12]. Group 4: Current Market Outlook - The biopharmaceutical market is expected to experience a recovery, with growth rates projected to improve from nearly zero to 1.2-1.4 times GDP growth, driven by easing pressures from social deflation and the adaptation to DRG policies [14][15]. - Despite the need to lower return expectations due to previous valuation recoveries, the overall outlook remains optimistic, particularly for domestic innovative drugs, U.S. biotech stocks, and innovative medical devices [15][17]. Group 5: Future Growth Potential - The domestic innovative drug sector is anticipated to maintain strong growth over the next decade, with revenue expected to increase from over 100 billion to 1 trillion, indicating significant market potential [17]. - The U.S. biotech sector is entering a commercialization phase that could unlock new multi-billion dollar market opportunities, while domestic innovative high-value consumables also show promise for substantial growth [17].

Industry Overview - The business development (BD) transactions for innovative drugs in China are experiencing significant growth, with expectations for further improvement in 2026 [2] - Multinational pharmaceutical companies (MNCs) have shifted their perspective towards China, now showing confidence in Chinese data and increasing interest in early-stage pipelines, not just clinical assets [2] - The regulatory environment for innovative drugs in China is improving, allowing for the possibility of global first approvals within China [2] Key Developments in 2026 - Significant advancements are anticipated in two areas: small nucleic acid drugs, which show promising clinical effects for chronic diseases, and T-cell engagers (TCEs), which are expected to make notable progress, particularly in treating small cell lung cancer [3] - The company Valiant Biopharma's key focus will be on its core pipeline LBL-024, a PD-1/41BB dual antibody, which is positioned as a foundational anti-tumor drug [3][4] Upcoming Milestones - The company plans to submit LBL-024 for market approval in China by mid-2026, with an expected approval in 2027 [4] - Phase II clinical trial results for LBL-024 are anticipated in 2026, indicating its broad-spectrum capabilities as an anti-tumor medication [4] - Four unique first-in-class drugs are being prepared for submission for new drug clinical trial licenses, expected to enter clinical development between 2026 and 2027 [5] Future Business Development - The company aims to enhance its BD efforts, emphasizing that success in BD will ultimately depend on the strength of its pipeline [6] - Valiant Biopharma is expected to become a significant player in the Chinese innovative drug industry regarding BD transactions [6]

Group 1 - The Chinese innovative drug industry has entered a critical stage of high-quality development, focusing on quality and core value rather than rapid scale expansion, moving from "barbaric growth" to "rational maturity" [2] - By 2026, the industry will emphasize core strengths and practical results, with a focus on producing valuable innovative outcomes and achieving efficient transformation [2] - Currently, the internationalization of Chinese innovative drugs is still in its early stages, with more early-stage pipelines engaging in license-out collaborations with multinational corporations (MNCs), reflecting global recognition of China's R&D capabilities [2] Group 2 - Innovative drug companies must adhere to their original intentions, focusing on unmet clinical needs rather than merely catering to business development transactions, with a goal to achieve FIC/BIC innovations to build core competitiveness [3] - Companies venturing abroad need to solidify their global capabilities by establishing a comprehensive self-operated system across R&D, production, commercialization, and regulatory compliance [3] - The new medical insurance directory and the first commercial insurance innovative drug directory are expected to enhance the accessibility of high-priced drugs and stabilize market expectations for companies [3] Group 3 - There is an opportunity for deep integration of digitalization and innovative drugs, with AI becoming a crucial tool for overcoming innovation bottlenecks and improving efficiency while reducing costs across various stages [4] - By 2026, the innovative drug industry will face both opportunities and challenges, with increasing industry concentration and a landscape where leading companies and niche leaders emerge [4] - The company aims to participate in the construction of the industry ecosystem by focusing on patient-centered approaches, aligning with innovation trends, ensuring compliance, and expanding collaboratively [4]

Company Overview - Recent positive developments in research for Ascentage Pharma, including the clinical approval of the next-generation BTK degrader APG-3288 by the National Medical Products Administration of China, have not significantly boosted the stock price, which has seen a decline of 0.38% in Hong Kong and 0.62% in the US from February 5 to February 12, 2026 [2] - The company's core product, Nairik, reported a 93% year-on-year increase in sales revenue to 217 million yuan in the first half of 2025, while the net loss widened to 591 million yuan due to reduced intellectual property licensing income and increased R&D investment [4] Industry Context - The innovative drug sector is under pressure, with a valuation correction for unprofitable biotech companies as the market shows impatience for long-term commercialization and focuses more on short-term profitability [3] - On February 12, 2026, there was a net outflow of 4.926 million HKD from major funds and 11.534 million HKD from retail investors in the Hong Kong stock market, indicating a risk-averse sentiment among short-term investors [3] Stock Performance - The stock price of Ascentage Pharma reached a low of 44.92 HKD on February 3, 2026, followed by a slight rebound; however, technical indicators suggest weak short-term momentum, with the MACD showing a bearish trend and KDJ in the oversold zone [5] - The stock's decline reflects market caution regarding the long-term valuation logic of innovative drug companies, as the recent R&D progress and improvements in fundamentals have not fully offset the pressures from sector adjustments and funding [5]

Company Overview - Shodex Bio (GPCR.OQ) has entered into a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million upfront payment and future royalties from oral GLP-1 drug sales [1] - The company's Q3 2025 financial report shows zero revenue and a net loss of $65.8 million, indicating ongoing R&D investments are pressuring short-term profitability [4] Stock Performance - As of February 12, 2026, Shodex Bio's stock price fell by 3.24% to $73.52, with a cumulative decline of 12.82% over the last 20 trading days [2] - The stock price peaked at $94.90 in January 2026 due to acquisition rumors but has since experienced a pullback, with a recent volatility of 22.57% and a low of $72.10 [5] Industry Context - Since January 2026, the pharmaceutical and biotechnology sector has seen accelerated thematic rotation, with profit-taking pressures emerging in the innovative drug field [3] - Concerns about intensified competition in the GLP-1 market, particularly regarding potential impacts from generic drugs, have led to increased caution among investors [3] Market Environment - On the same day, the Nasdaq index fell by 1.84%, reflecting a general increase in market risk aversion [6] - Shodex Bio's trading volume was approximately $24.58 million, indicating that low liquidity conditions may amplify stock price volatility [6]

Group 1 - The core focus for investment in the upcoming year includes three main areas: domestic AI ecosystem, innovative pharmaceuticals, and commercial aerospace [1][2] - The domestic AI industry is expected to replicate the growth trajectory seen overseas, with significant advancements in large model technology and semiconductor manufacturing [1] - The AI industry chain is anticipated to strengthen progressively, with downstream sectors centered around large models and cloud computing, and upstream sectors including AI chips, storage, semiconductor manufacturing, equipment, and materials [1] Group 2 - The innovative pharmaceutical sector has shown explosive growth over the past 2-3 years, despite a recent pullback due to valuation pressures; companies with international capabilities are seen as good investment opportunities [2] - The commercial aerospace industry is expected to accelerate commercialization over the next 5-10 years, driven by breakthroughs in rocket recovery and low-orbit satellite technologies, making it a sector worth close attention [2]

Core Viewpoint - The Hong Kong stock market is expected to continue the trends of 2025 into 2026, which may be a "reconstruction year" [2][3] Investment Focus Areas - The company is optimistic about three main sectors: 1. Technology sector, focusing on internet, electronic semiconductors, and innovative pharmaceuticals [2][4] 2. Upstream resource commodities, such as oil and coal, which may present good investment opportunities [2][5] 3. Outbound enterprises, with many globally competitive companies in the Hong Kong stock market worth attention [2][6] Market Trends and Variables - In the first half of 2026, the market is likely to favor strong performers, with domestic demand undergoing structural adjustments and the U.S. continuing its monetary easing [3][4] - Two key variables to monitor in the second half of 2026 include: 1. Stability of housing prices in first-tier cities, which could lead to valuation recovery in undervalued sectors like consumption, building materials, and real estate [4] 2. Potential inflation rebound and interest rate hikes following the U.S. midterm elections, which could impact global assets [4] Technology Sector Insights - The technology sector is expected to benefit from global capital and talent influx, with a focus on AI, semiconductors, and energy supply chains [5][6] - The "sell shovels" strategy is recommended, focusing on essential components for AI, such as domestic semiconductors and energy infrastructure [5] Upstream Resource Outlook - The company has maintained a positive outlook on upstream resource commodities for several years, anticipating opportunities in oil and coal if the Federal Reserve lowers interest rates and global industrialization continues [5][6] Outbound Enterprises Potential - Outbound enterprises are seen as a concentrated investment opportunity, with many capable of thriving beyond single market cycles and expected to grow in the future [6][7]